|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 894 USD | -0.80% |
|
-2.86% | +1.79% |
| Apr. 17 | UBS Adjusts Regeneron Pharmaceuticals Price Target to $1,099 From $1,090, Maintains Buy Rating | MT |
| Apr. 17 | The market is pinning its hopes on earnings reports |  |
May 4 (Reuters) - Regeneron Pharmaceuticals reported a 13% fall in quarterly profit on Wednesday, as sales of its COVID-19 antibody cocktail were hit by the U.S. health regulator's decision to limit their use. (Reporting by Leroy Leo in Bengaluru; Editing by Rashmi Aich and Shinjini Ganguli)
| 1st Jan change | Capi. | |
|---|---|---|
| +1.79% | 96.84B | |
| -3.30% | 102B | |
| -0.44% | 21.48B | |
| -18.35% | 20.82B | |
| -7.45% | 18.6B | |
| -40.31% | 16.81B | |
| -26.84% | 13.78B | |
| +0.59% | 13.4B | |
| +20.86% | 11.06B | |
| -21.69% | 8.88B |
REGENERON PHARMACEUTICALS, INC. 
